26 Sep 2022 --- US-based Eli Lilly and Company has received US Food and Drug Administration (FDA) approval for Lilly’s Mounjaro, a tirzepatide injection treatment for Type 2 diabetes. The approval makes it the “first and only” FDA-approved gastric inhibitory polypeptide and glucagon-like-peptide-1 receptor agonist, expected to be available in the US in the coming weeks. “Mounjaro delivered superior and consistent A1C reductions against all of the comparators throughout the Surpass program (the trial), which was designed to assess Mounjaro’s efficacy and safety in a broad range of adults with type 2 diabetes who could be treated in clinical practice,” says Juan Pablo Frías, medical director at the National Research Institute and investigator in the program. “The approval of Mounjaro is an exciting step forward for people living with type 2 diabetes given the results in these clinical trials.”
